Context Therapeutics Inc. - Common Stock (CNTX)

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class
Equity / Common Stock
Shares outstanding
91,837,471
Total 13F shares
3,558,639
Share change
+979,983
Total reported value
$4,020,714
Price per share
$1.13
Number of holders
24
Value change
+$1,102,318
Number of buys
9
Number of sells
2

Institutional Holders of Context Therapeutics Inc. - Common Stock (CNTX) as of Q4 2023

As of 31 Dec 2023, Context Therapeutics Inc. - Common Stock (CNTX) was held by 24 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,558,639 shares. The largest 10 holders included Opaleye Management Inc., Ally Bridge Group (NY) LLC, VANGUARD GROUP INC, Affinity Asset Advisors, LLC, UBS OCONNOR LLC, HighTower Advisors, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Mill Creek Capital Advisors, LLC, GEODE CAPITAL MANAGEMENT, LLC, and NORTHERN TRUST CORP. This page lists 24 institutional shareholders reporting positions in this security for the Q4 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.